 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Larry Allen and Laura Helmkamp.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.133 |
|
|
|
-
Swat SA, Helmkamp LJ, Tietbohl C, Thompson JS, Fitzgerald M, McIlvennan CK, Harger G, Ho PM, Ahmad FS, Ahmad T, Buttrick P, Allen LA. Clinical Inertia Among Outpatients With Heart Failure: Application of Treatment Nonintensification Taxonomy to EPIC-HF Trial. JACC Heart Fail. 2023 11; 11(11):1579-1591.
Score: 0.209
-
McIlvennan CK, Urra M, Helmkamp L, Messenger JC, Raymer D, Ream KS, Oldemeyer JB, Ambardekar AV, Barnes K, Allen LA. Magnitude of troponin elevation in patients with biomarker evidence of myocardial injury: relative frequency and outcomes in a cohort study across a large healthcare system. BMC Cardiovasc Disord. 2023 03 24; 23(1):151.
Score: 0.203
-
Allen LA, Venechuk G, McIlvennan CK, Page RL, Knoepke CE, Helmkamp LJ, Khazanie P, Peterson PN, Pierce K, Harger G, Thompson JS, Dow TJ, Richards L, Huang J, Strader JR, Trinkley KE, Kao DP, Magid DJ, Buttrick PM, Matlock DD. An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction: The EPIC-HF Trial. Circulation. 2021 02 02; 143(5):427-437.
Score: 0.173
-
Venechuk GE, Khazanie P, Page RL, Knoepke CE, Helmkamp LJ, Peterson PN, Pierce K, Thompson JS, Huang J, Strader JR, Dow TJ, Richards L, Trinkley KE, Kao DP, McIlvennan CK, Magid DJ, Buttrick PM, Matlock DD, Allen LA. An Electronically delivered, Patient-activation tool for Intensification of medications for Chronic Heart Failure with reduced ejection fraction: Rationale and design of the EPIC-HF trial. Am Heart J. 2020 11; 229:144-155.
Score: 0.170
-
McIlvennan CK, Grady KL, Matlock DD, Helmkamp LJ, Abshire M, Allen LA. End of life for patients with left ventricular assist devices: Insights from INTERMACS. J Heart Lung Transplant. 2019 04; 38(4):374-381.
Score: 0.151
-
Ilonze OJ, Helmkamp LJ, McIlvennan CK, Allen LA, Breathett K, Enyi CO, Page RL. Trends in urine drug screening and positivity among patients with heart failure: Insights from a large health system. Am Heart J. 2025 Dec; 290:226-229.
Score: 0.060
-
Lipsey J, Allen LA, Page RL, Helmkamp LJ, Venechuk G, Trinkley KE, Matlock DD, McIlvennan CK. Association of multimorbidity with guideline-directed medical therapy intensification in heart failure: Findings from the EPIC-HF trial. Heliyon. 2024 Jul 15; 10(13):e34178.
Score: 0.056
-
Wallace BC, Allen LA, Knoepke CE, Glasgow RE, Lewis CL, Fairclough DL, Helmkamp LJ, Fitzgerald MD, Tzou WS, Kramer DB, Varosy PD, Gupta SK, Mandrola JM, Brancato SC, Peterson PN, Matlock DD. A multicenter trial of a shared DECision Support Intervention for Patients offered implantable Cardioverter-DEfibrillators: DECIDE-ICD rationale, design, Medicare changes, and pilot data. Am Heart J. 2020 08; 226:161-173.
Score: 0.041
-
Breathett K, Allen LA, Helmkamp L, Colborn K, Daugherty SL, Blair IV, Jones J, Khazanie P, Mazimba S, McEwen M, Stone J, Calhoun E, Sweitzer NK, Peterson PN. Temporal Trends in Contemporary Use of Ventricular Assist Devices by Race and Ethnicity. Circ Heart Fail. 2018 08; 11(8):e005008.
Score: 0.037
-
Breathett K, Allen LA, Helmkamp L, Colborn K, Daugherty SL, Khazanie P, Lindrooth R, Peterson PN. The Affordable Care Act Medicaid Expansion Correlated With Increased Heart Transplant Listings in African-Americans But Not Hispanics or Caucasians. JACC Heart Fail. 2017 02; 5(2):136-147.
Score: 0.033
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|